Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2014

Date: July 15, 2014
Pages: 63
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: F6A4A848946EN
Leaflet:

Download PDF Leaflet

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2014
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2014’, provides an overview of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Overview
Therapeutics Development
Pipeline Products for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Overview
Pipeline Products for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Comparative Analysis
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Therapeutics under Development by Companies
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Therapeutics under Investigation by Universities/Institutes
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Products under Development by Companies
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Products under Investigation by Universities/Institutes
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Companies Involved in Therapeutics Development
Amgen Inc.
ReGenX Biosciences, LLC
Cerenis Therapeutics SA
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
evolocumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CER-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy To Activate LDL Receptor For Familial Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotides to Inhibit ApoB100 for Familial Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BSN-272 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Recent Pipeline Updates
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Dormant Projects
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Discontinued Products
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Product Development Milestones
Featured News & Press Releases
Jun 02, 2014: Cerenis Reports Two Positive Phase II Studies for HDL Mimetic CER-001 at EAS
Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins
Mar 27, 2014: Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session
Mar 27, 2014: Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study
Mar 24, 2014: Phase 3 Pivotal Data On Amgen's Novel Investigational Cholesterol-Lowering Medicine To Be Featured At The American College of Cardiology's 63rd Annual Scientific Session
Mar 17, 2014: Amgen Announces Positive Top-Line Results From Phase 3 TESLA Trial Of Evolocumab (AMG 145) In Patients With Homozygous Familial Hypercholesterolemia
Jan 28, 2014: Amgen Announces Positive Top-Line Results From Phase 3 LAPLACE-2 Trial Of Evolocumab (AMG 145) In Combination With Statins In Patients With High Cholesterol
Jan 23, 2014: Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-2 Trial Of Evolocumab (AMG 145) In Statin Intolerant Patients With High Cholesterol
Jan 02, 2014: Cerenis Reports Top-Line Phase II Results for its HDL Mimetic CER-001
Dec 19, 2013: Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab In Patients With High Cholesterol
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), H2 2014
Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Amgen Inc., H2 2014
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by ReGenX Biosciences, LLC, H2 2014
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Cerenis Therapeutics SA, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics - Recent Pipeline Updates, H2 2014
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Dormant Projects, H2 2014
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Discontinued Products, H2 2014

LIST OF FIGURES

Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), H2 2014
Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Target, H2 2014
Number of Products by Stage and Top 10 Target, H2 2014
Number of Products by Top 10 Mechanism of Action, H2 2014
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
Number of Products by Top 10 Route of Administration, H2 2014
Number of Products by Stage and Top 10 Route of Administration, H2 2014
Number of Products by Top 10 Molecule Type, H2 2014
Number of Products by Stage and Top 10 Molecule Type, H2 2014

COMPANIES MENTIONED

Amgen Inc.
ReGenX Biosciences, LLC
Cerenis Therapeutics SA
Hypercholesterolemia - Pipeline Review, Q4 2010 US$ 500.00 Dec, 2010 · 60 pages
Hypercholesterolemia - Pipeline Review, Q1 2011 US$ 500.00 Mar, 2011 · 58 pages
Hypercholesterolemia - Pipeline Review, H2 2013 US$ 2,000.00 Sep, 2013 · 120 pages

Ask Your Question

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: